FDA has approved Talzenna for gBRCAm HER2-negative locally advanced or metastatic breast cancer
The FDA ( Food and Drug Administration ) has approved Talzenna ( Talazoparib ), a poly (ADP-ribose) polymerase ( PARP ) inhibitor, for patients with deleterious or suspected deleterious germline BRCA- ...
read article